Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Non Small Cell Lung Cancer|Solid Tumors, Adult|Endometrial Cancer|Pancreatic Cancer|Cervical Cancer|Breast Cancer|Carcinoma of Unknown Primary
Interventions: DRUG: TNG260|DRUG: Pembrolizumab
Sponsor: Tango Therapeutics, Inc.